ProfileGDS5678 / 1430035_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 61% 60% 60% 58% 60% 59% 61% 59% 58% 57% 60% 60% 61% 59% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.657961
GSM967853U87-EV human glioblastoma xenograft - Control 23.5650760
GSM967854U87-EV human glioblastoma xenograft - Control 33.5679460
GSM967855U87-EV human glioblastoma xenograft - Control 43.4331358
GSM967856U87-EV human glioblastoma xenograft - Control 53.5619160
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.6318959
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.7525661
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.5638559
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.5061258
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.4370457
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.5797260
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.5774560
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.6472861
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.5570959